Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD. (CompareAcute)

31. Juli 2020 aktualisiert von: Maasstad Hospital

Fractional Flow Reserve Guided Primary Multivessel Percutaneous Coronary Intervention to Improve Guideline Indexed Actual Standard of Care for Treatment of ST-elevation Myocardial Infarction in Patients With Multivessel Coronary Disease

The Compare-Acute trial is a prospective randomised trial in patients with multivessel disease, who are admitted into hospital with a ST-elevation Myocardial Infarction. The purpose of the study is to compare a FFR guided multivessel PCI taking place during the primary PCI with a primary PCI of the culprit vessel only.

Patients will be enrolled after successful revascularisation of the culprit vessel. Patients that have at least one lesion with a diameter of stenosis of more than 50% on visual estimation, feasible (operators judgement) for treatment with PCI in a non-infarct related artery, will be randomised either to the FFR guided complete revascularisation arm or staged revascularisation by proven ischemia or persistence of symptoms of angina.

Approximately 885 patients will be entered in the study.

Study hypothesis: FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Background of the study: At the moment the general opinion is divided over the way the non culprit lesions in patients presenting with STEMI should be treated. While the previous guidelines stead that these lesions should be treated in a second time ( ie not during the primary intervention) the actual guidelines do not touch this argument. The reason is that the studies where the previous guidelines were based are old. Meanwhile small sized randomised trials from EU region have proven favourable outcomes with NON infarct related artery during the primary procedure while registers (non randomised trials) from USA still recommend the staged treatment. For this reason we have decided to perform a randomised study to address this issue incorporating the state of the art diagnosis and treatment, as well as the new medical therapy and PCI techniques.

Objective of the study: FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines

Study design: Prospective, 1: 2 randomisation. FFR guided revascularisation during primary PCI (1) versus following actual guidelines (2)

Study population: All STEMI patients between 18-85 years who will be treated with primary PCI in < 12 h (more than 12 hr if persisting pain allowed) after the onset of symptoms and have at least one stenosis of >50% in a non-IRA judged feasible for treatment with PCI.

Intervention (if applicable): FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines

Primary study parameters/outcome of the study: Composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Stroke (MACCE) at 12 months

Studientyp

Interventionell

Einschreibung (Tatsächlich)

885

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Deutschland
      • Bad Krozingen, Deutschland, 79189
        • Herz-Zentrum Bad Krozingen
      • Bad Segeberg, Deutschland, 23795
        • Herzzentrum Bad Segeberger Klinik
      • Bremen, Deutschland, 28277
        • Klinikum Links der Weser
      • Ingolstadt, Deutschland, 85049
        • Medizinische Klinik IV
      • Rostock, Deutschland, 18057
        • Medical University Rostock
  • Niederlande
      • Arnhem, Niederlande
        • Rijnstate Hospital
      • Groningen, Niederlande
        • University Medical Center Groningen
      • Heerlen, Niederlande
        • Atrium MC Parkstad
      • Maastricht, Niederlande
        • Maastricht Universitair Medical center
      • Rotterdam, Niederlande, 3079DZ
        • Maasstadhospital
      • The Hague, Niederlande, 2512 VA
        • Medisch Centrum Haaglanden
  • Norwegen
      • Oslo, Norwegen
        • Oslo University Hospital
  • Polen
      • Lubin, Polen
        • Miedziowe Centrum Zdrowia Lubin
      • Warsaw, Polen
        • Centralny Szpital Kliniczny MSWiA w Warszawie
      • Warsaw, Polen
        • Kliniki Kardiologii Allenort
      • Wroclaw, Polen
        • 4 Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ
  • Schweden
      • Goteborg, Schweden, 41315
        • Sahlgrenska Götheborg University Hospital
  • Singapur
      • Singapore, Singapur, 308433
        • Tan Tock Seng Hospital
      • Singapore, Singapur, 768828
        • Khoo Teck Puat Hospital
  • Tschechien
      • Brno, Tschechien
        • University Hospital Brno
      • Hradec Králové, Tschechien
        • University hospital Hradec Králové
      • Liberec, Tschechien
        • Liberec Regional Hospital
  • Ungarn
      • Budapest, Ungarn
        • Gottsegen György Országos Kardiológiai Intézet
      • Nyíregyháza, Ungarn
        • Szabolcs - Szatmár - Bereg County Hospitals and University Teaching Hospital
      • Szeged, Ungarn
        • Szent-Györgyi Albert Klinika
      • Zalaegerszeg, Ungarn
        • Zala Megyei Kórház

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 85 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • All patients between 18-85 years presenting with STEMI who will be treated with primary PCI in < 12 h after the onset of symptoms* and have at least one stenosis of >50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator.

    • Patients with symptoms for more than 12 hr but ongoing angina complaints can be randomised

Exclusion Criteria:

  1. Left main stem disease (stenosis > 50%)
  2. STEMI due to in-stent thrombosis
  3. Chronic total occlusion of a non-IRA
  4. Severe stenosis with TIMI flow ≤ II of the non-IRA artery.
  5. Non-IRA stenosis not amenable for PCI treatment (operators decision)

  6. Complicated IRA treatment, with one or more of the following;

    • Extravasation,
    • Permanent no re-flow after IRA treatment (TIMI flow 0-1),
    • Inability to implant a stent
  7. Known severe cardiac valve dysfunction that will require surgery in the follow-up period.
  8. Killip class III or IV already at presentation or at the completion of culprit lesion treatment.
  9. Life expectancy of < 2 years.
  10. Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, Bivaluridin, or Everolimus and known true anaphylaxis to prior contrast media of bleeding diathesis or known coagulopathy.
  11. Gastrointestinal or genitourinary bleeding within the prior 3 months,
  12. Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment.
  13. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
  14. Pregnancy or planning to become pregnant any time after enrolment into this study.
  15. Inability to obtain informed consent.
  16. Expected lost to follow-up.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: FFR-guided revascularisation strategy
In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of >0.80 will not be treated.
Verfahren: FFR-guided revascularisation strategy
FFR-guided revascularisation strategy
Placebo-Komparator: randomised to guidelines group
In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
Verfahren: randomised to guidelines group
Staged revascularisation by proven ischemia or persistence of symptoms of angina

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants With the Composite Endpoint of MACCE
Zeitfenster: 12 months
Number of participants with the composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Cerebrovascular Events (MACCE) at 12 months between groups
12 months
Number of Participants With Death From Any Cause
Zeitfenster: 12 months
Number of participants with all cause mortality at 12 months between groups
12 months
Number of Participants With Cardiac Death
Zeitfenster: 12 months
Number of participants with Cardiac mortality at 12 months between groups
12 months
Number of Participants With Spontaneous MI
Zeitfenster: 12 months
Number of participants with Spontaneous Myocardial Infarction at 12 months between groups
12 months
Number of Participants With Periprocedural MI
Zeitfenster: 12 months
Number of participants with Periprocedural Myocardial Infarction at 12 months between groups
12 months
Number of Participants With Revascularization - PCI
Zeitfenster: 12 months
Number of participants with revascularization PCI at 12 months between groups
12 months
Number of Participants With Revascularization - CABG
Zeitfenster: 12 months
Number of participants with revascularization CABG at 12 months between groups
12 months
Number of Participants With Cerebrovascular Event
Zeitfenster: 12 months
Number of participants with Cerebrovascular event at 12 months between groups
12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants With Composite Endpoint of NACE (Any First Event)
Zeitfenster: 12 months
Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 12 months (NACE i.e. Net Adverse Clinical Events)
12 months
Number of Participants With Death From Any Cause or MI
Zeitfenster: 12 months
Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 12 months
12 months
Number of Participants With Major Bleeding
Zeitfenster: 12 months
Number of participants with Major bleeding at 12 months - Part of composite NACE
12 months
Number of Participants With Any Bleeding at 12 Months
Zeitfenster: 12 months
Number of participants with any bleeding at 12 months - part of composite endpoint NACE
12 months
Number of Participants With Any Bleeding at 48 Hours
Zeitfenster: 48 hours
Number of participants with any bleeding at 48 hours - part of composite endpoint NACE
48 hours
Number of Participants With Hospitalization
Zeitfenster: 12 months
Number of participants with hospitalization for heart failure, unstable angina or chest pain
12 months
Number of Participants With Revascularization
Zeitfenster: 12 months
Number of participants with any revascularization-Part of composite endpoint NACE
12 months
Number of Participants With Stent Thrombosis
Zeitfenster: 12 months
Number of participants with Stent Thrombosis - Part of composite endpoint NACE
12 months
Number of Participants With Primary Endpoint Outcome MACCE (Any First Event) at 3 Year
Zeitfenster: 3 year
Number of participants with Composite primary endpoint MACCE (any first event) at 3 year
3 year
Number of Participants With All Cause Death at 3 Year
Zeitfenster: 3 year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - all cause death
3 year
Number of Participants With Cardiac Death at 3 Year
Zeitfenster: 3 year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - Cardiac death
3 year
Number of Participants With Spontaneous MI at 3 Year
Zeitfenster: 3 year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - Spontaneous MI
3 year
Number of Participants With Peri-procedural MI at 3 Year
Zeitfenster: 3 year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - Peri-procedural MI
3 year
Number of Participants With Urgent Revascularization at 3 Year
Zeitfenster: 3 year
Number of participants with Composite endpoint MACCE (any first event) at 3 year - urgent revascularisation
3 year
Number of Participants With Elective Revascularization at 3 Year
Zeitfenster: 3 year
Number of participants with Composite endpoint MACCE (any first event) at 3 year -elective revascularisation
3 year
Number of Participants With Cerebrovascular Event
Zeitfenster: 3 year
Number of participants with Composite endpoint MACCE (any first event) at 3 year -Cerebrovascular event
3 year
Number of Participants With Composite Endpoint of NACE (Any First Event) at 3 Year
Zeitfenster: 3 years
Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 3 year (NACE i.e. Net Adverse Clinical Events)
3 years
Number of Participants With Death From Any Cause or MI
Zeitfenster: 3 year
Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 3 year
3 year
Number of Participants With Major Bleeding at 3 Year
Zeitfenster: 3 year
Number of participants with Part of composite endpoint NACE- Major bleeding at 3 year
3 year
Number of Participants With Hospitalization
Zeitfenster: 3 year
Number of participants with Hospitalization for heart failure, unstable angina, MI
3 year
Number of Participants With Hospitalization at 3 Year
Zeitfenster: 3 year
Number of participants with Hospitalization for heart failure, unstable angina, MI and/or chest pain
3 year
Number of Participants With Stent Thrombosis at 3 Year
Zeitfenster: 3 year
Number of participants with Stent Thrombosis at 3 year - Part of composite endpoint NACE
3 year
Number of Participants With Any Bleeding at 3 Year
Zeitfenster: 3 year
Number of participants with any bleeding at 3 year - Part of composite endpoint NACE
3 year

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
A Comparison of the Number of Patients in Both Groups With Treated Lesions With FFR ≤ 0.80 Versus Patients With Untreated Lesions With FFR ≤ 0.80;
Zeitfenster: 3 year
FFR+/PCI+ vs FFR+/PCI- Comparison of patients having FFR positive lesions that underwent revascularization during index procedure or in staged procedures within 45 days (groups A+C, n=202 patients) with patients having FFR positive lesions that did not undergo revascularization (group D, n=231 patients),
3 year
Comparison of Acute Versus Staged PCI for Lesions With FFR ≤ 0.80
Zeitfenster: 3 year
Comparison of acute versus staged PCI treatment for lesions with FFR
3 year
Comparison of PCI vs Medical Therapy in FFR Negative Lesions
Zeitfenster: 3 year
comparison of patients receiving staged PCI treatment of FFR-negative lesions in the non-IRA (decision made by referring physician who was blinded to FFR results) and patients receiving medical therapy for FFR-negative lesions in the non-IRA
3 year

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Maasstad Hospital

Mitarbeiter

Abbott Medical Devices

Ermittler

  • Hauptermittler: Peter Smits, MD. PHD, Maastadhospital / MCR
  • Studienstuhl: Elmir Omerovic, MD PhD, Sahlgrenska Hospital Götheborg
  • Studienstuhl: Gert Richardt, MD PhD, Herzzentrum Segeberger Kliniken
  • Studienstuhl: Franz-Josef Neumann, MD PhD, Herz-Zentrum Bad Krozingen

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Juli 2011

Primärer Abschluss (Tatsächlich)

31. Oktober 2016

Studienabschluss (Tatsächlich)

31. Oktober 2018

Studienanmeldedaten

Zuerst eingereicht

20. Juli 2011

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. Juli 2011

Zuerst gepostet (Schätzen)

22. Juli 2011

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

11. August 2020

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

31. Juli 2020

Zuletzt verifiziert

1. Mai 2020

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • Compare-Acute

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Kuwait

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren